HK1205469A1 - Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency - Google Patents

Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Info

Publication number
HK1205469A1
HK1205469A1 HK15106135.6A HK15106135A HK1205469A1 HK 1205469 A1 HK1205469 A1 HK 1205469A1 HK 15106135 A HK15106135 A HK 15106135A HK 1205469 A1 HK1205469 A1 HK 1205469A1
Authority
HK
Hong Kong
Prior art keywords
methods
visual
disorders associated
therapeutic regimens
endogenous retinoid
Prior art date
Application number
HK15106135.6A
Other languages
English (en)
Chinese (zh)
Inventor
Suzanne Cadden
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of HK1205469A1 publication Critical patent/HK1205469A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
HK15106135.6A 2012-03-01 2015-06-29 Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency HK1205469A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605729P 2012-03-01 2012-03-01
US201261642212P 2012-05-03 2012-05-03
US201261644360P 2012-05-08 2012-05-08
PCT/CA2013/050155 WO2013134867A1 (fr) 2012-03-01 2013-03-01 Schémas et procédé thérapeutiques utilisés pour améliorer la fonction visuelle dans les troubles de la vue associés à une carence en rétinoïdes endogènes

Publications (1)

Publication Number Publication Date
HK1205469A1 true HK1205469A1 (en) 2015-12-18

Family

ID=49160185

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106135.6A HK1205469A1 (en) 2012-03-01 2015-06-29 Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Country Status (17)

Country Link
US (2) US20160296478A1 (fr)
EP (1) EP2819667B8 (fr)
JP (3) JP6576636B2 (fr)
KR (1) KR102133608B1 (fr)
CN (2) CN104470511A (fr)
AU (3) AU2013232697B2 (fr)
BR (1) BR112014021602A2 (fr)
CA (1) CA2865935C (fr)
DK (1) DK2819667T3 (fr)
ES (1) ES2780357T3 (fr)
HK (1) HK1205469A1 (fr)
IL (1) IL234306B (fr)
MX (1) MX370928B (fr)
NZ (1) NZ629267A (fr)
PT (1) PT2819667T (fr)
RU (1) RU2635536C2 (fr)
WO (1) WO2013134867A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939081A (zh) 2010-04-19 2013-02-20 Qlt股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2015164419A1 (fr) * 2014-04-22 2015-10-29 Acucela Inc. Evaluation pupillométrique de pharmacodynamies rétiniennes et réactions correspondantes
WO2018091937A1 (fr) 2016-11-17 2018-05-24 University Of Debrecen Composés précurseurs pour obtenir des rétinoïdes de la voie de la vitamine a5 et leurs utilisations
US20180170867A1 (en) * 2015-05-08 2018-06-21 University Of Debrecen Stereoselective synthesis of 9-cis.13,14-dihydroretinoic acid and its ethyl esters
US20190054056A1 (en) * 2015-05-08 2019-02-21 University Of Debrecen Precursor compounds for providing retinoids of the vatamin a5 pathway and uses thereof
RU186184U1 (ru) * 2018-06-06 2019-01-11 Федеральное государственное бюджетное учреждение "33 Центральный научно-исследовательский испытательный институт" Министерства обороны Российской Федерации Устройство для оценки углов обзора и поля зрения испытателей в противогазе

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (fr) 1973-08-21 1977-07-29 Hoffmann La Roche
US4022913A (en) 1973-09-13 1977-05-10 Hoffmann-La Roche Inc. High potency vitamin A compositions
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
CA1198859A (fr) 1982-04-21 1986-01-07 Chester L. O'neal Brosse a dent jetable avec etui
US4532133A (en) 1983-05-24 1985-07-30 Basf Wyandotte Corporation Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (fr) 1984-12-14 1991-04-02 Paul J. Jarosz Compose pharmaceutique contenant de la vitamine a 13-cis acide comme ingredient actif
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (fr) 1994-04-04 1997-01-22 FREEMAN, William R. Emploi de nucleosides de phosphonylemethoxyalkyle pour traiter la pression intra-oculaire elevee
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
EP0839029A1 (fr) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Solution claire et stable d'anti-inflammatoires non steroidiens a integrer dans des gelules de gelatine
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (fr) 1997-08-23 1999-04-14 Werner Bollag Traitement de troubles immunitaires induits par les cellules
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
EP1261623B1 (fr) 2001-01-11 2009-11-04 Chebigen Inc. Nouveaux derives de retinol, procede de preparation et d'utilisation de ceux-ci
EP1381276A4 (fr) 2001-04-13 2005-02-02 Univ Pennsylvania Traitement soignant ou retardant l'installation de la cecite
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
WO2003045379A1 (fr) 2001-11-30 2003-06-05 Kinetek Pharmaceuticals, Inc. Derives d'hydrazonopyrazole et leur utilisation comme agents therapeutiques
JP2005524626A (ja) 2002-01-18 2005-08-18 タットン テクノロジーズ エルエルシー． 眼疾患を治療するための方法
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2003082081A2 (fr) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Utilisation de la production de rom et d'inhibiteurs de liberation pour traiter et prevenir des dommages intraoculaires
JP3854524B2 (ja) 2002-04-01 2006-12-06 ピアス株式会社 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1367493A1 (fr) 2002-05-30 2003-12-03 STMicroelectronics Limited Tampon de préextraction
EP1527774A1 (fr) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG Formulations nouvelle pour retinoides contenant capsules de gélatine molle
EP2327400A3 (fr) 2003-03-14 2011-10-19 University of Washington Substituts de retinoides et agonistes d'ospine et methodes d'utilisation correspondantes
EP1510133A1 (fr) 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Composition d'huile équilibrée
EP2412303B1 (fr) 2003-09-04 2015-11-25 The UAB Research Foundation Procédé et dispositif pour la détection de l'adaptation à l'obscurité diminuée
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
EP1722766A2 (fr) 2004-02-17 2006-11-22 President And Fellows Of Harvard College Gestion de troubles ophtalmologiques, notamment la degenerescence maculaire
EP1723096A4 (fr) 2004-03-04 2008-03-05 Htl High Tech Lipids Ltd Triglycerides structures et emulsions contenant ces triglycerides
WO2005087210A2 (fr) 2004-03-17 2005-09-22 Lars Michael Larsen Prevention de la retinopathie par inhibition du cycle visuel
CN102976937B (zh) * 2004-06-18 2016-12-21 华盛顿大学 用于治疗视觉障碍的视黄醛衍生物及其使用方法
SG140607A1 (en) 2004-06-23 2008-03-28 Sirion Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20060240098A1 (en) 2004-07-14 2006-10-26 Aphios Corporation Formulations for hyperforin-enriched hypericum fractions
CA2575265A1 (fr) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Procedes de combinaison, compositions et therapies permettant de traiter des etats opthalmiques par des derives de 13-cis-retinyle
WO2006039551A2 (fr) * 2004-09-30 2006-04-13 The Regents Of The University Of California Administration locale de retinoides pour traiter les deficiences de l'adaptation a l'obscurite
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
JP2009514890A (ja) 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
US8202541B2 (en) 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
CA2657015A1 (fr) 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Composes stabilisant les opsines et procedes d'utilisation
CA2972344C (fr) 2007-01-15 2021-10-26 Chongxi Yu Promedicaments positivement charges solubles dans l'eau de retinoides et de composes semblables a des retinoides ayant des vitesses de penetration dans la peau tres elevees
JP5149388B2 (ja) 2007-09-12 2013-02-20 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 黄斑変性症を処置するための組成物及び方法
KR20160092032A (ko) 2008-02-11 2016-08-03 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 연령-관련 망막 기능장애의 치료 및 예방 방법
WO2011034551A2 (fr) 2009-09-15 2011-03-24 Qlt Inc. Préparations pharmaceutiques à base de 9-cis-retinyl esters dans un véhicule lipidique
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
CN102939081A (zh) 2010-04-19 2013-02-20 Qlt股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Also Published As

Publication number Publication date
AU2013232697A1 (en) 2014-09-18
ES2780357T3 (es) 2020-08-25
EP2819667A4 (fr) 2015-08-05
CA2865935C (fr) 2021-12-14
AU2018200415A1 (en) 2018-02-08
DK2819667T3 (da) 2020-03-30
CN104470511A (zh) 2015-03-25
EP2819667B8 (fr) 2020-03-04
AU2013232697B2 (en) 2017-10-19
KR20150000881A (ko) 2015-01-05
JP2017197588A (ja) 2017-11-02
RU2014139666A (ru) 2016-04-20
WO2013134867A1 (fr) 2013-09-19
BR112014021602A2 (pt) 2021-06-08
AU2019283995A1 (en) 2020-01-23
JP6576636B2 (ja) 2019-09-18
MX370928B (es) 2020-01-08
KR102133608B1 (ko) 2020-07-13
EP2819667B1 (fr) 2019-12-25
AU2018200415B2 (en) 2019-09-26
CN109248163A (zh) 2019-01-22
IL234306B (en) 2022-02-01
JP2020073597A (ja) 2020-05-14
JP2015508783A (ja) 2015-03-23
RU2635536C2 (ru) 2017-11-13
AU2019283995B2 (en) 2021-11-11
CA2865935A1 (fr) 2013-09-19
US20160296478A1 (en) 2016-10-13
US20190054039A1 (en) 2019-02-21
US10828267B2 (en) 2020-11-10
MX2014010457A (es) 2015-04-08
NZ629267A (en) 2016-11-25
PT2819667T (pt) 2020-03-31
EP2819667A1 (fr) 2015-01-07

Similar Documents

Publication Publication Date Title
HK1205469A1 (en) Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
GB2514658B (en) Improvements in and relating to displays
HK1204271A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
EP2798639A4 (fr) Dispositif et procédé d'autotest et de réparation intégré
EP2969063A4 (fr) Appareil de course avec plateformes réglables et procédés associés
PL2855065T3 (pl) Sposób i układ do spawania manualnego
GB201321829D0 (en) Headache-treatment device with gel dispensing kit and method
EP2736474A4 (fr) Dispositif et procédé de thérapie neuromusculaire
HK1214274A1 (zh) 用於治療肝臟疾病和心血管疾病的脂肽
PL3065759T3 (pl) Środki immunosupresyjne i ich zastosowanie w leczeniu
EP2863205A4 (fr) Procédé et dispositif d'évaluation de la peau
GB201305822D0 (en) Improvements in and relating to apparatus and methods
EP2914225A4 (fr) Dispositif et méthode de réparation rétinienne
GB201216649D0 (en) Agents and methods
EP2745148A4 (fr) Outils et procédés de diagraphie focalisée de résistivité à réseaux multiples au moyen d'électrodes de surveillance séparées
HK1246171A1 (zh) 用於治療或改善與內源性類視黃醇缺乏有關的視覺障礙的治療方案和方法
PT2670769T (pt) R2r1/2 em diagnóstico e terapêutica
EP2846708A4 (fr) Procédés et appareil de stimulation de récepteurs d'étirement dans le système vasculaire
EP2999524A4 (fr) Dispositif associé à un exercice
GB201319273D0 (en) Improvements in structural members and methods relating thereto
GB201312244D0 (en) Training in balancing skills
EP2893042A4 (fr) Test de diagnostic de la démence et procédés associés
GB201303203D0 (en) Improvements in and relating to storage apparatus
EP2822455A4 (fr) Procédés et moyens d'évaluation de troubles hépatiques
GB2515520B (en) Improvements in and relating to displays